Volume 5, Supplement 4Supplement5-Alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic HyperplasiaClaus G RoehrbornBenign prostatic hyperplasiaLower urinary tract symptomsAcute urinary
Volume 5, Supplement 4SupplementBenign Prostatic Hyperplasia: Does Prostate Size Matter?J Curtis NickelBenign prostatic hyperplasiaAcute urinary retentionProstate volume
Volume 5, Supplement 4SupplementClinical Evaluation of Benign Prostatic HyperplasiaKevin T McVaryBenign prostatic hyperplasiaLower urinary tract symptomsClinical evaluation
Volume 5, Supplement 2SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Kenneth J PientaHoward M SandlerProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
Volume 5, Supplement 2SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
Volume 5, Supplement 2SupplementInitial Experience with Single-Agent Docetaxel as Neoadjuvant Therapy in Men with Locally Advanced Prostate CancerRobert DreicerEric A KleinLocally advanced prostate cancerRadical prostatectomyNeoadjuvant
Volume 5, Supplement 2SupplementBiochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen TaplinProstate cancerProstate-specific antigenAdjuvantBiochemical relapse
Volume 5, Supplement 2SupplementCaP CURE Initiatives and ProjectsHoward R SouleProstate cancerProstate-specific antigenCaP CURE